STOCK TITAN
  1. Home
  2. News
  3. CLGN

CollPlant Biotechnologies Ltd Ordinary Shares - $CLGN STOCK NEWS

Welcome to our dedicated page for CollPlant Biotechnologies Ordinary Shares news (Ticker: $CLGN), a resource for investors and traders seeking the latest updates and insights on CollPlant Biotechnologies Ordinary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CollPlant Biotechnologies Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CollPlant Biotechnologies Ordinary Shares's position in the market.

News
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) announces financial results for 2023, highlighting progress in dermal filler and regenerative breast implant programs. The company ended 2023 with $26.7 million in cash. Collaboration with AbbVie and Stratasys advanced, triggering milestone payments. Regenerative breast implants showed promise in large-animal studies, targeting a $2.9 billion market. Intellectual property gains and ESG efforts were also notable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
earnings
-
News
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) schedules conference call to discuss financial results for the full year of 2023 on April 4, 2024, at 10:00 a.m. U.S. EDT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
earnings
-
News
CollPlant Issues Letter to Shareholders
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) CEO Yehiel Tal highlights key achievements in 2023, including progress with AbbVie collaboration and Stratasys partnership. The company focuses on regenerative and aesthetic medicine, with a pipeline of innovative products like regenerative breast implants and gut-on-a-chip tissue model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
News
CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) CEO to present at Octane Aesthetic Tech Forum on 3D Bioprinted Regenerative Breast Implants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) Initiates Pre-Clinical Trial for Regenerative Breast Implants, Aiming to Revolutionize the $2.6 Billion Market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
clinical trial
-
News
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
Rhea-AI Summary
CollPlant Biotechnologies (Nasdaq: CLGN) announced a $10 million milestone payment from partner AbbVie Inc., a $29 million cash runway, and financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.63%
Tags
earnings
News
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) to report Q3 2023 financial results on November 29, 2023, followed by a conference call and webcast. Investors can participate in the call using the provided dial-in information or the Call me™ feature. A live webcast will also be available, and questions for management can be submitted in advance via email.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
earnings
-
News
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler
Rhea-AI Summary
CollPlant Biotechnologies has secured a patent from the U.S. Patent and Trademark Office for its photocurable dermal filler product candidate. The patent covers a method of filling tissue space under the epidermis by introducing a polymerizable filler solution and applying external light for in-situ polymerization. This patent strengthens CollPlant's intellectual property in the U.S. market and expands the potential uses for its rhCollagen technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.11%
Tags
none
-
News
CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative
Rhea-AI Summary
CollPlant Biotechnologies joins UN Global Compact to strengthen commitment to sustainability in regenerative and aesthetics medicine industry
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
News
CollPlant to Present at the H.C. Wainwright Annual Growth Conference
Rhea-AI Summary
CollPlant Biotechnologies to participate in H.C Wainwright Annual Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
conferences
Stock CLGN logo
CollPlant Biotechnologies Ltd Ordinary Shares

Nasdaq:CLGN

CLGN Rankings

#4565 Ranked by Market Cap
#3243 Ranked by Stock Gains
N/A Ranked by Dividends

CLGN Stock Data

67.75M
7.82M
10.16%
12.23%
0.09%
Surgical Appliance and Supplies Manufacturing
Manufacturing
Link
United States of America
P O Box 4132

About CLGN

collplant is a regenerative medicine company focused on 3d bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. our products are based on our rhcollagen (recombinant human collagen) that is produced with collplant’s proprietary plant based genetic engineering technology. our products address indications for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. our flagship rhcollagen bioink product line is ideal for 3d bioprinting of tissues and organs, and our unique vergenix line of rhcollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds. collplant is a public company listed on the tel aviv stock exchange and on nasdaq (clgn).